Skip to main content
SpringerLink
Log in

Epithelial Ovarian Cancer

  • Chapter
  • First Online:
Contemporary Obstetrics and Gynecology for Developing Countries

  • 1232 Accesses

Abstract

Epithelial ovarian cancer is characterised by multiple histological subtypes and molecular diversity. Recent evidence indicates that most serous ovarian cancers originate from malignant tubal epithelium, while endometrioid and clear cell ovarian cancers develop most likely from endometriosis. The treatment of ovarian cancer consists of frontline cytoreductive surgery followed by adjuvant chemotherapy, or neo-adjuvant chemotherapy followed by surgery and additional chemotherapy. Although ovarian cancers usually respond well to first-line platinum-based chemotherapy, most patients develop recurrence, chemo-resistance and progressive disease. This chapter provides knowledge about ovarian cancer risk factors, screening, diagnostic work up, standard chemotherapy and the use of newer agents such as anti-angiogenesis and poly-ADP-ribose polymerase inhibitor inhibition.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ramalingam P. Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer. Oncology (Williston Park). 2016;30(2):166–76.

    Google Scholar 

  2. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2013. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER website, April 2016.

  3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.

    Article  CAS  PubMed  Google Scholar 

  4. Rescigno P, Cerillo I, Ruocco R, Condello C, De Placido S, Pensabene M. New hypothesis on pathogenesis of ovarian cancer leads to future tailored approaches. Biomed Res Int. 2013;2013:852839.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lalwani N, Prasad SR, Vikram R, et al. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics. 2011;31:625–46.

    Article  PubMed  Google Scholar 

  6. Lee K, Young R. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281–92.

    Article  PubMed  Google Scholar 

  7. Ioka A, Tsukuma H, Ajiki W, Oshima A. Ovarian cancer incidence and survival by histologic type in Osaka, Japan. Cancer Sci. 2003;94(3):292–6.

    Article  CAS  PubMed  Google Scholar 

  8. Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016;293(4):695–700.

    Article  PubMed  Google Scholar 

  9. Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151–60.

    PubMed  PubMed Central  Google Scholar 

  10. Vang R, Shih I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267–82.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36:861–70.

    Article  CAS  PubMed  Google Scholar 

  13. Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Antoniou A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Krawczyk N, Banys-Paluchowski M, Schmidt D, Ulrich U, Fehm T. Endometriosis-associated malignancy. Geburtshilfe Frauenheilkd. 2016;76(2):176–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Chene G, Caloone J, Moret S, Le Bail-Carval K, Chabert P, Beaufils E, Mellier G, Lamblin G. Is endometriosis a precancerous lesion? Perspectives and clinical implications. Gynecol Obstet Fertil. 2016;44(2):106–12.

    Article  CAS  PubMed  Google Scholar 

  17. Lin HW, Tu YY, Lin SY, Su WJ, Lin WL, Lin WZ, Wu SC, Lai YL. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12(9):900–4.

    Article  PubMed  Google Scholar 

  18. Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet. 1971;2(7716):163.

    Article  CAS  PubMed  Google Scholar 

  19. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71(4):717–21.

    CAS  PubMed  Google Scholar 

  20. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990;50(23):7415–21.

    CAS  PubMed  Google Scholar 

  21. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F, Trichopoulos D, Beral V. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer. 1991;49(1):57–60.

    Article  CAS  PubMed  Google Scholar 

  22. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. “Incessant ovulation” and ovarian cancer. Lancet. 1979;2(8135):170–3.

    Article  CAS  PubMed  Google Scholar 

  23. Sallam HN, Abdel-Bak M, Sallam NH. Does ovulation induction increase the risk of gynaecological cancer? Facts Views Vis Obgyn. 2013;5(4):265–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004;82(2):405–14.

    Article  PubMed  Google Scholar 

  25. Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F, Beral V, Boyle P, Trichopoulos D. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer. 1991;49:50–6.

    Article  CAS  PubMed  Google Scholar 

  26. Riman T, Persson I, Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol (Oxf). 1998;49(6):695–707.

    Article  CAS  Google Scholar 

  27. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control. 2007;18(5):517–23.

    Article  PubMed  Google Scholar 

  28. Titus-Ernstoff L, Rees JR, Terry KL, Cramer DW. Breast-feeding the last born child and risk of ovarian cancer the last child. Cancer Causes Control. 2010;21(2):201–7.

    Article  PubMed  Google Scholar 

  29. Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, Terry KL. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study. Int J Cancer. 2013;133(10):2415–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ovarian cancer statistics. Available on line from https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer. Accessed 3 June 2019.

  31. Olsen CM, Cnossen J, Green AC, Webb PM. Comparison of symptoms and presentation of women with benign, low malignant potential and invasive ovarian tumours. Eur J Gynaecol Oncol. 2007;28(5):376–80.

    CAS  PubMed  Google Scholar 

  32. Behtash N, Ghayouri Azar E, Fakhrejahani F. Symptoms of ovarian cancer in young patients 2 years before diagnosis, a case-control study. Eur J Cancer Care (Engl). 2008;17(5):483–7.

    Article  CAS  Google Scholar 

  33. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921–6.

    CAS  PubMed  Google Scholar 

  34. RCOG. Management of suspected ovarian masses in premenopausal women. Green-top guideline no. 62. London: RCOG; 2011. Available online from https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_62.pdf. Accessed 2 June 2019.

    Google Scholar 

  35. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922–9.

    Article  CAS  PubMed  Google Scholar 

  36. Mol BW, Boll D, De Kanter M, Heintz AP, Sijmons EA, Oei SG, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol. 2001;80:162–7.

    Article  CAS  PubMed  Google Scholar 

  37. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, Van Holsbeke C, Savelli L, Fruscio R, Lissoni AA, Testa AC, Veldman J, Vergote I, Van Huffel S, Bourne T, Valentin L. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Bookman M, Berek J. Biologic and immunologic therapy of ovarian cancer. Hematol Oncol Clin North Am. 1992;6:941–65.

    Article  CAS  PubMed  Google Scholar 

  39. Eisenkop SM, Friedman RL, Wang H-J. Complete cytoreductive surgery is feasible and maximises survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69:103–8.

    Article  CAS  PubMed  Google Scholar 

  40. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

    Article  CAS  PubMed  Google Scholar 

  41. Winter-Roach B, Hooper L, Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int J Gynecol Cancer. 2003;13(4):395–4.

    Article  CAS  PubMed  Google Scholar 

  42. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomised trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynaecologic Oncology Group). Semin Oncol. 1996;23(5 Suppl 12):40–7.

    CAS  PubMed  Google Scholar 

  43. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360(9332):505–15.

    Article  Google Scholar 

  44. Osman MA, Elkady MS, Nasr KE. Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin Med Insights Oncol. 2016;10:35–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.

    Article  CAS  PubMed  Google Scholar 

  46. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose intravenous carboplatin followed by intraperitoneal paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian cancer: an intergroup study of the Gynaecologic Oncology Group, Southwestern Oncology Group, and the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.

    Article  CAS  PubMed  Google Scholar 

  47. Chan DL, Morris DL, Rao A, Chua TC. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res. 2012;4:413–22.

    PubMed  PubMed Central  Google Scholar 

  48. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006;25(1):CD005340. https://doi.org/10.1002/14651858.CD005340.pub2.

    Article  Google Scholar 

  49. Zhang W, Shen Z, Luo H, Hu X, Zheng L, Zhu X. The benefits and side effects of bevacizumab for the treatment of recurrent ovarian cancer. Curr Drug Targets. 2017;18(10):1125–31. https://doi.org/10.2174/1389450117666160502150237.

    Article  CAS  PubMed  Google Scholar 

  50. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Cohen JG, White M, Cruz A, Farias-EIsner R. In 2014, can we do better than CA-125 in the early detection of ovarian cancer ? World J Biol Chem. 2014;5(3):286–300.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ. 1996;313(7069):1355–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49(3):521–5. https://doi.org/10.1515/CCLM.2011.075.

    Article  CAS  PubMed  Google Scholar 

  55. Terlikowska KM, Dobrzycka B, Witkowska AM, Mackowiak-Matejczyk B, Sledziewski TK, Kinalski M, Terlikowski SJ. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res. 2016;9(1):43.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Abbas AM, Zahran KM, Nasr A, Kamel HS. A new scoring model for characterisation of adnexal masses based on two-dimensional gray-scale and colour Doppler sonographic features. Facts Views Vis Obgyn. 2014;6(2):68–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Bourne T, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and color blood flow imaging. BMJ. 1993;306:1025–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Jacobs IJ, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria

    Olusegun Kayode Ajenifuja

  2. Obafemi Awolowo University Teaching Hospitals, Ile-Ife, Nigeria

    Olusegun Kayode Ajenifuja

  3. Roswell Park Comprehensive Cancer Centre (Roswell Park), Buffalo, NY, USA

    Kunle Odunsi

  4. Department of Gynaecologic Oncology, Centre for Immunotherapy, Roswell Park, Buffalo, NY, USA

    Kunle Odunsi

  5. University of Buffalo, Buffalo, NY, USA

    Kunle Odunsi

Authors
  1. Olusegun Kayode Ajenifuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kunle Odunsi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kunle Odunsi .

Editor information

Editors and Affiliations

  1. Centre of Excellence in Reproductive Health Innovation, Department of Obstetrics and Gynaecology, University of Benin, Benin City, Nigeria

    Friday Okonofua

  2. College of Health Sciences, Chicago State University, Chicago, IL, USA

    Joseph A. Balogun

  3. Roswell Park Cancer Institute, Buffalo, NY, USA

    Kunle Odunsi

  4. Clinical Obstetrics and Gynaecology, Weil Cornell Medicine, Doha, Qatar

    Victor N. Chilaka

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ajenifuja, O.K., Odunsi, K. (2021). Epithelial Ovarian Cancer. In: Okonofua, F., Balogun, J.A., Odunsi, K., Chilaka, V.N. (eds) Contemporary Obstetrics and Gynecology for Developing Countries . Springer, Cham. https://doi.org/10.1007/978-3-030-75385-6_58

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-75385-6_58

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-75384-9

  • Online ISBN: 978-3-030-75385-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation